Efficacy and safety of triple therapy with vonoprazan for Helicobacter pylori eradication: A multicenter, prospective, randomized controlled trial

doi:10.3748/wjg.v31.i28.109001

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 31, Issue 28

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (2145)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-3) series, Tables (1-4) series.

Item

Count

PDF

HTML

1144

Figures (1-3)

379

Tables (1-4)

Sum=1619

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

150

Download

228

Sum=378

Publishing Process of This Article

Item

Count

Browse

Download

Sum=76

Jul 28, 2025 (publication date) through Aug 12, 2025

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Randomized Controlled Trial

World J Gastroenterol. Jul 28, 2025; 31(28): 109001
Published online Jul 28, 2025. doi: 10.3748/wjg.v31.i28.109001

Table 1 Baseline characteristics and demographics, n (%)

Characteristics	EBAC group (n = 175)	VACa group (n = 175)	VACb group (n = 174)
Age (year), mean ± SD	47.27 ± 11.48	48.20 ± 11.65	47.21 ± 11.70
Female sex	82 (46.9)	91 (52.0)	94 (54.0)
Married	170 (97.1)	162 (92.6)	161 (92.5)
Weight (kg), mean ± SD	68.36 ± 10.40	67.03 ± 10.95	66.74 ± 10.31
Height (cm), mean ± SD	168.18 ± 8.44	167.41 ± 7.49	167.36 ± 8.49
BMI, mean ± SD	24.12 ± 2.94	23.82 ± 2.85	23.78 ± 2.81
Smoking	19 (10.9)	14 (8.0)	16 (9.2)
Alcohol intake	54 (30.9)	43 (24.6)	46 (26.4)
High blood pressure	26 (14.9)	22 (12.6)	13 (7.5)
Diabetes	9 (5.1)	8 (4.6)	4 (2.3)
Family history of gastric cancer	14 (8.0)	9 (5.1)	6 (3.4)
History of peptic ulcer
No peptic ulcers	164 (93.7)	166 (94.9)	169 (97.1)
Gastric ulcer	5 (2.9)	7 (4.0)	4 (2.3)
Duodenal ulcer	6 (3.4)	2 (1.1)	1 (0.6)
Helicobacter pylori infection in family members	57 (32.6)	47 (26.9)	57 (32.8)

BMI: Body mass index; EBAC: Esomeprazole/bismuth/amoxicillin/clarithromycin; VACa: 14-day vonoprazan/amoxicillin/clarithromycin; VACb: 10-day vonoprazan/amoxicillin/clarithromycin.

Citation: Han RS, Hao JW, Wang T, Xin Z, Fan GX, Wang GD, Liu MM, Liu CX, Yang QZ, Yang ZW, Lv XY, Zhang C, Bian G, Meng J, Cui ZQ, Yun XJ, Cao JH, Li SH, Fan JF, Ma HG, Gao FY, Mao T, Tian ZB, Song XH, Yu YN. Efficacy and safety of triple therapy with vonoprazan for Helicobacter pylori eradication: A multicenter, prospective, randomized controlled trial. World J Gastroenterol 2025; 31(28): 109001
URL: https://www.wjgnet.com/1007-9327/full/v31/i28/109001.htm
DOI: https://dx.doi.org/10.3748/wjg.v31.i28.109001